Mouse ST6GALNAC2 Protein (His Tag)

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Protein Datasheet

ST6GALNAC2 Protein Product Information

• Synonym: RP23-313J14.1, II, ST6GalNAc, Siat7, Siat7b
• Protein Construction: A DNA sequence encoding the extracellular domain of mouse ST6GALNAC2 (P70277) (Ser 28-Arg 373) was expressed, with a C-terminal polyhistidine tag.
• Source: Mouse
• Expression Host: Human Cells

ST6GALNAC2 Protein QC Testing

• Purity: > 98 % as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ser 28
• Molecular Mass: The secreted recombinant mouse ST6GALNAC2 comprises 357 amino acids and has a calculated molecular mass of 40.7 kDa. The apparent molecular mass of rmST6GALNAC2 is approximately 44 kDa in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: ST6GALNAC2 protein

ST6GALNAC2 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

ST6GALNAC2 Protein Description

Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2, also known as STHM or ST6GALNAC2, is a protein belonging to a family of sialyltransferases that add sialic acids to the nonreducing ends of glycoconjugates. STHM / ST6GALNAC2 is a typeⅡ membrane protein localized in the Golgi network and catalyzes 2,6-sialylation of the Tn antigen. The protein is highly expressed in lactating mammary gland and adult testis and lower levels in kidney. Disregulation of the encoding gene is involved in synthesizing a cancer vaccine and in pathogenesis of IgA nephropathy, a common kidney disease that occurs when antibody IgA accumulates in kidneys. Aberrant O-galactosylation of IgA1 molecules plays a role in the development and progression of IgA nephropathy (IgAN). Genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity, and may contribute to the polygenic nature of IgAN.

References

1. Li GS. et al., 2007, Hum Mutat. 28 (10): 950-7.
2. Ding JX. et al., 2009, Scand J Immunol. 69 (2): 174-80.
3. Kiryluk K. et al., 2010, Pediatr Nephrol. 25 (11): 2257-68.